Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Selected Publications

Full publication list available on PubMed

  • Bulman, ZP, Wicha, SG, Nielsen, EI, Lenhard, JR, Nation, RL, Theuretzbacher, U, Derendorf, H, Tängdén, T, Zeitlinger, M, Landersdorfer, CB, Bulitta, JB, Friberg, LE, Li, J, Tsuji, BT, Pharmacology, International Society of Anti-Infective, Group, European Society of Clinical Microbiology and Infectious Diseases Pharmacokinetics and Pharmacodynamics of Anti-Infectives Study, Group, International Society of Antimicrobial Chemotherapy Anti-Infective Pharmacology Working. Research priorities towards precision antibiotic therapy to improve patient care. The Lancet Microbe. 2022. doi: 10.1016/s2666-5247(22)00121-5.
  • Huang, Y, Rana, AP, Wenzler, E, Ozer, EA, Krapp, F, Bulitta, JB, Hauser, AR, Bulman, ZP. Aminoglycoside-resistance gene signatures are predictive of aminoglycoside MICs for carbapenem-resistant Klebsiella pneumoniae. 2021. Journal of Antimicrobial Chemotherapy, 77, (2), 356-363. doi: 10.1093/jac/dkab381.
  • Bulman, ZP, Krapp, F, Pincus, NB, Wenzler, E, Murphy, KR, Qi, C, Ozer, EA, Hauser, AR. Genomic Features Associated with the Degree of Phenotypic Resistance to Carbapenems in Carbapenem-Resistant Klebsiella pneumoniae. 2021. mSystems, 6, (5), e00194-e00121. doi: 10.1128/msystems.00194-21.
  • Huang, Y, Sokolowski, K, Rana, A, Singh, N, Wang, J, Chen, K, Lang, Y, Zhou, J, Kadiyala, N, Krapp, F, Ozer, EA, Hauser, AR, Li, J, Bulitta, JB, Bulman, ZP. Generating Genotype-Specific Aminoglycoside Combinations with Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae. 2021. Antimicrobial Agents and Chemotherapy, 65, (9), e00692-e00621. doi: 10.1128/aac.00692-21.
  • Sumon ZE, Berenson CS, Sellick JA, Bulman ZP, Tsuji BT, Mergenhagen KA. "Successful cure of daptomycin-non-susceptible, vancomycin-intermediate Staphylococcus aureus prosthetic aortic valve endocarditis directed by synergistic in vitro time-kill study.". Infectious diseases (London, England). 2019;:1-6. doi:10.1080/23744235.2018.1533646.
  • Bulman ZP, Zhao M, Satlin MJ, Chen L, Kreiswirth BN, Walsh TJ, Nation RL, Li J, Tsuji BT. "Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model.". International journal of antimicrobial agents. 2018;52(1):114-118. doi:10.1016/j.ijantimicag.2018.02.010.
  • Smith NM, Bulman ZP, Sieron AO, Bulitta JB, Holden PN, Nation RL, Li J, Wright GD, Tsuji BT. "Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli.". J Antimicrob Chemother. 2017;(72(8)):2297-2303. doi:10.1093/jac/dkx121.
  • Bulman ZP, Zhao M, Lenhard JR, Satlin MJ, Kreiswirth BN, Walsh TJ, Marrocco A, Bergen PJ, Nation RL, Li J, Zhang J, Tsuji BT. "Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae". J Antimicrob Chemother. 2017;(72(7)):1985-1990. doi:10.1093/jac/dkx070.
  • Bulman ZP, Chen L, Walsh TJ, Satlin MJ, Qian Y, Bulitta B, Peloquin CA, Holden PN, Nation RL, Li J, Kreiswirth BN, Tsuji BT. "Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and blaNDM-5: Preparation for a Postantibiotic Era". mBio. 2017;(8(4). pii: e00540-17). doi:10.1128/mBio.00540-17.
  • Shafiq I, Bulman ZP, Spitznogle SL, Osorio JE, Reilly IS, Lesse AJ, Parameswaran GI, Mergenhagen KA, Tsuji BT. "A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA)". Infectious diseases (London, England). 2017;49(5):410-416. doi:10.1080/23744235.2016.1277587.
  • Bulman ZP, Ly NS, Lenhard JR, Holden PN, Bulitta JB, Tsuji BT. "Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.". Antimicrobial agents and chemotherapy. 2017;61(4). doi:10.1128/AAC.00096-16.
  • Bulman ZP, Satlin MJ, Chen L, Kreiswirth BN, Shin BS, Walsh TJ, Holden PN, Forrest A, Nation RL, Li J, Tsuji BT. "New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae". Antimicrobial agents and chemotherapy. 2017;61(4). doi:10.1128/AAC.02023-16.
  • Lenhard JR, Smith NM, Bulman ZP, Tao X, Thamlikitkul V, Shin BS, Nation RL, Li J, Bulitta JB, Tsuji BT. "High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model". Antimicrobial agents and chemotherapy. 2017;61(3). doi:10.1128/AAC.01268-16.
  • Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT. "In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.". International journal of antimicrobial agents. 2017;49(1):25-30. doi:10.1016/j.ijantimicag.2016.07.015.
  • Brotzki CR, Mergenhagen KA, Bulman ZP, Tsuji BT, Berenson CS. "Native valve Proteus mirabilis endocarditis: successful treatment of a rare entity formulated by in vitro synergy antibiotic testing.". BMJ case reports. 2016;2016. doi:10.1136/bcr-2016-215956.
  • Bulman ZP, Ly NS,  Bulitta JB, Baron C, Rao GG, Holden PN, Li J, Sutton MD, Tsuji BT. "Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa.". Antimicrobial agents and chemotherapy. 2016;60(5):2870-80. doi:10.1128/AAC.02377-15.
  • Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT. "Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.". Antimicrobial agents and chemotherapy. 2016;60(4):1967-73. doi:10.1128/AAC.02635-15.
  • Lenhard JR, Brown T, Rybak MJ, Meaney CJ, Norgard NB, Bulman ZP, Brazeau DA, Gill SR, Tsuji BT. "Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.". Antimicrobial agents and chemotherapy. 2015;60(3):1584-91. doi:10.1128/AAC.02657-15.
  • Bergen PJ, Bulman ZP, Landersdorfer CB, Smith N, Lenhard JR, Bulitta JB, Nation RL, Li J, Tsuji BT. "Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria.". Infectious diseases and therapy. 2015;4(4):391-415. doi:10.1007/s40121-015-0093-7.
  • Bulman ZP, Sutton MD, Ly NS, Bulitta JB, Holden PN, Nation RL, Li J, Tsuji BT. "Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutators.". Antimicrobial agents and chemotherapy. 2015;59(7):4343-6. doi:10.1128/AAC.04629-14.
  • Lenhard JR, von Eiff C, Hong IS, Holden PN, Bear MD, Suen A, Bulman ZP, Tsuji BT. "Evolution of Staphylococcus aureus under vancomycin selective pressure: the role of the small-colony variant phenotype.". Antimicrobial agents and chemotherapy. 2015;59(2):1347-51. doi:10.1128/AAC.04508-14.
  • Bergen PJ, Bulman ZP, Saju S, Bulitta JB, Landersdorfer C, Forrest A, Li J, Nation RL, Tsuji BT. "Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.". Pharmacotherapy. 2015;35(1):34-42. doi:10.1002/phar.1537.
  • Bulman ZP, Le P, Hudson AO, Savka MA. "A novel property of propolis (bee glue): anti-pathogenic activity by inhibition of N-acyl-homoserine lactone mediated signaling in bacteria.". Journal of ethnopharmacology. 2011;138(3):788-97. doi:10.1016/j.jep.2011.10.029.